The herg screening market size has grown rapidly in recent years. It will grow from $1.84 billion in 2025 to $2.06 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to rising incidences of cardiac-related drug withdrawals, increasing investment in preclinical safety studies, growth of pharmaceutical R&D, adoption of in-vitro ion channel assays, increasing awareness of drug-induced arrhythmias.
The herg screening market size is expected to see rapid growth in the next few years. It will grow to $3.21 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in ai-driven predictive toxicology, integration of organ-on-chip technologies, growth of biologics and personalized medicine, rising outsourcing to cdmos, expansion in emerging markets preclinical research. Major trends in the forecast period include advanced cardiotoxicity modeling, high-throughput screening automation, integration of predictive analytics in preclinical safety, expansion of contract research services, miniaturized microfluidic assays.
The increase in the number of patients with heart disorders is expected to drive the growth of the HERG screening market in the coming years. Heart disorders, also referred to as cardiovascular diseases, encompass a range of conditions affecting the heart and blood vessels. These conditions can impair the heart’s functionality and may lead to serious health complications. Heart disorders can result from unhealthy lifestyles, aging, genetic factors, diabetes, and metabolic syndrome. HERG screening helps identify potential drug candidates, prevent adverse cardiac events that may cause life-threatening arrhythmias such as torsade de pointes (TdP), and improve patient outcomes. For instance, in October 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, an estimated 57,100 adults aged 25 and above experienced acute coronary events, averaging approximately 156 incidents per day. Therefore, the rise in the number of patients with heart disorders is propelling growth in the HERG screening market.
The growing aging population is also expected to drive the growth of the HERG screening market. An aging population refers to an increasing proportion of older individuals within a society due to longer life expectancy and declining birth rates. This demographic is expanding as advancements in healthcare extend life expectancy. HERG screening plays a role in ensuring that new drugs are safe for elderly patients by identifying compounds that could cause harmful cardiac side effects. For instance, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. During this period, this age group’s share of the total U.S. population is projected to grow from 17% to 23%. Therefore, the rise in the aging population is driving growth in the HERG screening market.
Major companies in the HERG screening market are focusing on innovative, advanced solutions, such as GLP-certified HERG screening services, to improve cardiac safety assessments during drug development. This service involves good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the conventional whole-cell patch-clamp technique, ensuring compliance with regulatory guidelines such as ICH S7A and ICH S7B, which are critical for safety pharmacology studies. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched a GLP-certified hERG screening service. This service aims to strengthen Metrion’s support for small-molecule therapeutic development and complement the company’s existing cardiac safety service portfolio. It employs the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before Phase 1 clinical trials, provides regulatory guidance for safety pharmacology studies, and offers clients high-quality biology services for ion channel targets.
Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.
North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herg screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the HERG screening market by increasing the cost of imported laboratory instruments, reagents, and precision testing equipment, creating supply chain disruptions particularly in North America and Europe. Segments like high-throughput screening systems and automated assay platforms are most affected, while regions relying on imports from Asia-Pacific face delays. However, tariffs have also encouraged local manufacturing and innovation in assay development, potentially strengthening regional capabilities and reducing long-term dependency on foreign suppliers.
The herg screening market research report is one of a series of new reports that provides herg screening market statistics, including herg screening industry global market size, regional shares, competitors with a herg screening market share, detailed herg screening market segments, market trends and opportunities, and any further data you may need to thrive in the herg screening industry. This herg screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Human Ether-à-go-go-related gene (HERG) screening refers to the process of evaluating the potential cardiotoxicity of a drug or compound. HERG screening is a critical part of preclinical safety assessments in drug discovery and development, helping to ensure the safety and effectiveness of new therapeutic agents.
The main types of HERG screening are gene KCNH2 and mutant KCNH2. The gene KCNH2, also known as the human ether-à-go-go-related gene (hERG), encodes the alpha subunit of a potassium ion channel that is essential for regulating the heart’s electrical activity. It involves various ion channels, including voltage-gated and ligand-gated channels, and is applied in areas such as antiarrhythmics, antipsychotics, antibiotics, and other therapeutic applications.
The HERG screening market includes revenues earned by entities by providing services such as in vitro HERG assays, patch clamp electrophysiology, data analysis and interpretation, consultation and regulatory support, and customized assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The herg screening market size is expected to see rapid growth in the next few years. It will grow to $3.21 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in ai-driven predictive toxicology, integration of organ-on-chip technologies, growth of biologics and personalized medicine, rising outsourcing to cdmos, expansion in emerging markets preclinical research. Major trends in the forecast period include advanced cardiotoxicity modeling, high-throughput screening automation, integration of predictive analytics in preclinical safety, expansion of contract research services, miniaturized microfluidic assays.
The increase in the number of patients with heart disorders is expected to drive the growth of the HERG screening market in the coming years. Heart disorders, also referred to as cardiovascular diseases, encompass a range of conditions affecting the heart and blood vessels. These conditions can impair the heart’s functionality and may lead to serious health complications. Heart disorders can result from unhealthy lifestyles, aging, genetic factors, diabetes, and metabolic syndrome. HERG screening helps identify potential drug candidates, prevent adverse cardiac events that may cause life-threatening arrhythmias such as torsade de pointes (TdP), and improve patient outcomes. For instance, in October 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, an estimated 57,100 adults aged 25 and above experienced acute coronary events, averaging approximately 156 incidents per day. Therefore, the rise in the number of patients with heart disorders is propelling growth in the HERG screening market.
The growing aging population is also expected to drive the growth of the HERG screening market. An aging population refers to an increasing proportion of older individuals within a society due to longer life expectancy and declining birth rates. This demographic is expanding as advancements in healthcare extend life expectancy. HERG screening plays a role in ensuring that new drugs are safe for elderly patients by identifying compounds that could cause harmful cardiac side effects. For instance, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. During this period, this age group’s share of the total U.S. population is projected to grow from 17% to 23%. Therefore, the rise in the aging population is driving growth in the HERG screening market.
Major companies in the HERG screening market are focusing on innovative, advanced solutions, such as GLP-certified HERG screening services, to improve cardiac safety assessments during drug development. This service involves good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the conventional whole-cell patch-clamp technique, ensuring compliance with regulatory guidelines such as ICH S7A and ICH S7B, which are critical for safety pharmacology studies. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched a GLP-certified hERG screening service. This service aims to strengthen Metrion’s support for small-molecule therapeutic development and complement the company’s existing cardiac safety service portfolio. It employs the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before Phase 1 clinical trials, provides regulatory guidance for safety pharmacology studies, and offers clients high-quality biology services for ion channel targets.
Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.
North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herg screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the HERG screening market by increasing the cost of imported laboratory instruments, reagents, and precision testing equipment, creating supply chain disruptions particularly in North America and Europe. Segments like high-throughput screening systems and automated assay platforms are most affected, while regions relying on imports from Asia-Pacific face delays. However, tariffs have also encouraged local manufacturing and innovation in assay development, potentially strengthening regional capabilities and reducing long-term dependency on foreign suppliers.
The herg screening market research report is one of a series of new reports that provides herg screening market statistics, including herg screening industry global market size, regional shares, competitors with a herg screening market share, detailed herg screening market segments, market trends and opportunities, and any further data you may need to thrive in the herg screening industry. This herg screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Human Ether-à-go-go-related gene (HERG) screening refers to the process of evaluating the potential cardiotoxicity of a drug or compound. HERG screening is a critical part of preclinical safety assessments in drug discovery and development, helping to ensure the safety and effectiveness of new therapeutic agents.
The main types of HERG screening are gene KCNH2 and mutant KCNH2. The gene KCNH2, also known as the human ether-à-go-go-related gene (hERG), encodes the alpha subunit of a potassium ion channel that is essential for regulating the heart’s electrical activity. It involves various ion channels, including voltage-gated and ligand-gated channels, and is applied in areas such as antiarrhythmics, antipsychotics, antibiotics, and other therapeutic applications.
The HERG screening market includes revenues earned by entities by providing services such as in vitro HERG assays, patch clamp electrophysiology, data analysis and interpretation, consultation and regulatory support, and customized assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. HERG Screening Market Characteristics
3. HERG Screening Market Supply Chain Analysis
4. Global HERG Screening Market Trends and Strategies
5. HERG Screening Market Analysis of End Use Industries
7. Global HERG Screening Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global HERG Screening Total Addressable Market (TAM) Analysis for the Market
9. HERG Screening Market Segmentation
10. HERG Screening Market Regional and Country Analysis
11. Asia-Pacific HERG Screening Market
12. China HERG Screening Market
13. India HERG Screening Market
14. Japan HERG Screening Market
15. Australia HERG Screening Market
16. Indonesia HERG Screening Market
17. South Korea HERG Screening Market
18. Taiwan HERG Screening Market
19. South East Asia HERG Screening Market
20. Western Europe HERG Screening Market
21. UK HERG Screening Market
22. Germany HERG Screening Market
23. France HERG Screening Market
24. Italy HERG Screening Market
25. Spain HERG Screening Market
26. Eastern Europe HERG Screening Market
27. Russia HERG Screening Market
28. North America HERG Screening Market
29. USA HERG Screening Market
30. Canada HERG Screening Market
31. South America HERG Screening Market
32. Brazil HERG Screening Market
33. Middle East HERG Screening Market
34. Africa HERG Screening Market
36. HERG Screening Market Competitive Landscape and Company Profiles
37. HERG Screening Market Other Major and Innovative Companies
40. HERG Screening Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
HERG Screening Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses herg screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for herg screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The herg screening market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Gene KCNH2; Mutant KCNH22) By Ion Channel: Voltage-Gated; Ligand Gated
3) By Applications: Antiarrhythmic; Antipsychotic; Antibiotics; Other Applications
Subsegments:
1) By Gene KCNH2: Wild-Type KCNH2; Recombinant KCNH22) By Mutant KCNH2: Mutations: Missense Mutations; Nonsense Mutations; Frameshift Mutations
Companies Mentioned: Eurofins-Cerep SA; Aviva Biosciences Inc.; AstraZeneca Public Limited Company; Merck KGaA; Charles River Laboratories Inc.; Abcam Public Limited Company; Molecular Devices LLC; Caliper Life Sciences Inc.; ChanTest Corporation; Creative Bioarray Inc.; Cellular Dynamics International Inc.; Nanion Technologies; Essen Bioscience; ACEA Biosciences Inc.; Metrion Biosciences Inc.; Aurora Biomed Inc.; Aureus Sciences; RedShift BioAnalytics; Sophion Bioscience Inc.; Fluxion Biosciences Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this HERG Screening market report include:- Eurofins-Cerep SA
- Aviva Biosciences Inc.
- AstraZeneca Public Limited Company
- Merck KGaA
- Charles River Laboratories Inc.
- Abcam Public Limited Company
- Molecular Devices LLC
- Caliper Life Sciences Inc.
- ChanTest Corporation
- Creative Bioarray Inc.
- Cellular Dynamics International Inc.
- Nanion Technologies
- Essen Bioscience
- ACEA Biosciences Inc.
- Metrion Biosciences Inc.
- Aurora Biomed Inc.
- Aureus Sciences
- RedShift BioAnalytics
- Sophion Bioscience Inc.
- Fluxion Biosciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.06 Billion |
| Forecasted Market Value ( USD | $ 3.21 Billion |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
